Surrogate end points in women's health research: science, protoscience, and pseudoscience

Fertility and Sterility

Volumn 93, Issue 6, 2010, Pages 1731-1734

  Grimes, David A ^a   Schulz, Kenneth F ^a   Raymond, Elizabeth G ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; BIOLOGICAL MARKER; CONTRACEPTIVE AGENT; DROSPIRENONE; ENCAINIDE; FLECAINIDE; FLUORIDE; GESTAGEN; LEVONORGESTREL; LIDOCAINE; LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; SEX HORMONE BINDING GLOBULIN; VIRUS RNA;

ADOPTION; ARTICLE; BENEFICENCE; BLOOD CLOTTING TEST; BONE DENSITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEATH; EMPIRICISM; FRACTURE; GENETIC PREDISPOSITION; HEART INFARCTION; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMOSTASIS; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LIPOPROTEIN BLOOD LEVEL; MEDICAL ETHICS; NOMENCLATURE; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTOSCIENCE; PSEUDOSCIENCE; SCIENCE; THROMBOSIS; TREATMENT OUTCOME; VALIDATION STUDY; VALIDITY; VENOUS THROMBOEMBOLISM; VIRUS LOAD; WOMEN'S HEALTH;

BIOLOGICAL MARKERS; FEMALE; HEALTH PLANNING GUIDELINES; HUMANS; RESEARCH; SCIENCE; VALIDATION STUDIES AS TOPIC; WOMEN'S HEALTH;

EID: 77949913488     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.12.054     Document Type: Article

References (32)

1. Benowitz S. Biomarker boom slowed by validation concerns. J Natl Cancer Inst 96 (2004) 1356-1357
2. Grimes D.A., and Schulz K.F. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol 105 (2005) 1114-1118
3. Moore T. Deadly medicine: why tens of thousands of heart patients died in America's worst drug disaster (1995), Simon & Schuster, New York
4. Manns B., Owen Jr. W.F., Winkelmayer W.C., Devereaux P.J., and Tonelli M. Surrogate markers in clinical studies: problems solved or created?. Am J Kidney Dis 48 (2006) 159-166
5. Hine L.K., Laird N., Hewitt P., and Chalmers T.C. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Arch Intern Med 149 (1989) 2694-2698
6. Grimes D.A. Technology follies. The uncritical acceptance of medical innovation. JAMA 269 (1993) 3030-3033
7. Goldstein J., Cushman M., Badger G.J., and Johnson J.V. Effect of depomedroxyprogesterone acetate on coagulation parameter: a pilot study. Fertil Steril 87 (2007) 1267-1270
8. U.S. Food and Drug Administration. Black box warning added concerning long-term use of Depo-Provera contraceptive injection. Available at: http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM166395.pdf. Accessed January 27, 2010.
9. Kaunitz A.M. Depo-Provera's black box: time to reconsider?. Contraception 72 (2005) 165-167
10. van Rooijen M., Silveira A., Thomassen S., Hansson L.O., Rosing J., Hamsten A., et al. Rapid activation of haemostasis after hormonal emergency contraception. Thromb Haemost 97 (2007) 15-20
11. van Rooijen M., Silveira A., Hamsten A., and Bremme K. Sex hormone-binding globulin-a surrogate marker for the prothrombotic effects of combined oral contraceptives. Am J Obstet Gynecol 190 (2004) 332-337
12. van Vliet H.A., Winkel T.A., Noort I., Rosing J., and Rosendaal F.R. Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb Haemost 2 (2004) 2060-2062
13. Dinger J.C., Heinemann L.A., and Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75 (2007) 344-354
14. Johnson J.V., Lowell J., Badger G.J., Rosing J., Tchaikovski S., and Cushman M. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. Obstet Gynecol 111 (2008) 278-284
15. Stedman's Medical Dictionary. 27th ed (2000), Lippincott Williams & Wilkins, Philadelphia
16. Giuffre M. Science, bad science, and pseudoscience. J Perianesth Nurs 12 (1997) 434-438
17. Wikipedia. Protoscience. Available at: http://en.wikipedia.org/wiki/Protoscience. Accessed December 21, 2009.
18. Comp P.C. Thrombophilic mechanisms of OCs. Int J Fertil Womens Med Suppl 1 (1997) 170-176
19. Wikipedia. Pseudoscience. Available at: http://en.wikipedia.org/wiki/Pseudoscience. Accessed August 10, 2009.
20. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
21. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69 (2001) 89-95
22. De Gruttola V.G., Clax P., DeMets D.L., Downing G.J., Ellenberg S.S., Friedman L., et al. Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. Control Clin Trials 22 (2001) 485-502
23. Fleming T.R., and DeMets D.L. Surrogate end points in clinical trials: are we being misled?. Ann Intern Med 125 (1996) 605-613
24. Fleming T.R. Surrogate endpoints and FDA's accelerated approval process. Health Aff (Millwood) 24 (2005) 67-78
25. Riggs B.L., Hodgson S.F., O'Fallon W.M., Chao E.Y., Wahner H.W., Muhs J.M., et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322 (1990) 802-809
26. Kleerekoper M., Peterson E.L., Nelson D.A., Phillips E., Schork M.A., Tilley B.C., et al. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int 1 (1991) 155-161
27. Albert J.M., Ioannidis J.P., Reichelderfer P., Conway B., Coombs R.W., Crane L., et al. Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop. Stat Med 17 (1998) 2435-2462
28. Raymond E.G. Progestin-only pills. In: Hatcher R.A., Trussell J., Nelson A.L., Cates Jr. W., Stewart F., and Kowal D. (Eds). Contraceptive technology. 19th ed (2007), Ardent Media, New York 181-191
29. Alvarez F., Brache V., Faundes A., Tejada A.S., and Thevenin F. Ultrasonographic and endocrine evaluation of ovarian function among Norplant implants users with regular menses. Contraception 54 (1996) 275-279
30. American College of Obstetricians and Gynecologists. Ethics in obstetrics and gynecology. 2nd ed (2004), American College of Obstetricians and Gynecologists, Washington, DC
31. Echt D.S., Liebson P.R., Mitchell L.B., Peters R.W., Obias-Manno D., Barker A.H., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324 (1991) 781-788
32. Schafer A. The ethics of the randomized clinical trial. N Engl J Med 307 (1982) 719-724